Brief: Galapagos Presents Encouraging New Data For Cd19 Car-T Candidate Glpg5101 In Non-Hodgkin Lymphoma At Eha 2024

Lakefront Biotherapeutics NV

14/06/2024 22:09

Galapagos NV  GLPG.AS :
    * GALAPAGOS PRESENTS ENCOURAGING NEW DATA FOR CD19 CAR-T
CANDIDATE
GLPG5101 IN NON-HODGKIN LYMPHOMA AT EHA 2024
    * GALAPAGOS NV - GLPG5101 SHOWED AN ENCOURAGING SAFETY
PROFILE
WITH MOST TEAES OF GRADE 1 OR 2 IN ONGOING PHASE 1/2 ATALANTA-1
STUDY
    * GALAPAGOS NV - IN PHASE 2, 14 OF 15 EFFICACY-EVALUABLE
PATIENTS
RESPONDED TO TREATMENT (ORR 93.3%), AND ALL RESPONDERS ACHIEVED
A COMPLETE RESPONSE

Source text for Eikon:  ID:nGNXbw7gS 
Further company coverage:  GLPG.AS